Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

PubWeight™: 3.56‹?› | Rank: Top 1%

🔗 View Article (PMC 3412626)

Published in Lancet Oncol on March 07, 2012

Authors

Garnet L Anderson1, Rowan T Chlebowski, Aaron K Aragaki, Lewis H Kuller, JoAnn E Manson, Margery Gass, Elizabeth Bluhm, Stephanie Connelly, F Allan Hubbell, Dorothy Lane, Lisa Martin, Judith Ockene, Thomas Rohan, Robert Schenken, Jean Wactawski-Wende

Author Affiliations

1: Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA 98109, USA. garnet@whi.org

Associated clinical trials:

Women's Health Initiative (WHI) | NCT00000611

Articles citing this

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol (2015) 3.64

The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health (2013) 2.85

Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45

Covariate measurement error correction methods in mediation analysis with failure time data. Biometrics (2014) 2.10

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92

Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer (2016) 1.47

Postoophorectomy estrogen use and breast cancer risk. Obstet Gynecol (2012) 1.46

Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst (2015) 1.44

Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42

Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst (2015) 1.41

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20

Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev (2014) 1.17

Risk determination and prevention of breast cancer. Breast Cancer Res (2014) 1.11

c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res (2013) 1.09

Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08

Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause (2013) 1.00

Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. Endocrinology (2015) 0.96

Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer (2013) 0.95

Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res (2014) 0.95

Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93

Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res (2012) 0.93

Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93

Moving a randomized clinical trial into an observational cohort. Clin Trials (2012) 0.93

Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91

The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer (2014) 0.90

Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer (2014) 0.90

Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One (2013) 0.89

Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res (2015) 0.88

Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. Gynecol Oncol (2015) 0.87

Hormone therapy and young-onset breast cancer. Am J Epidemiol (2015) 0.87

Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer. Mol Pharmacol (2014) 0.85

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). Steroids (2014) 0.84

Epidemiology and treatment of osteoporosis in women: an Indian perspective. Int J Womens Health (2015) 0.84

Oestrogen and breast cancer: results from the WHI trial. Lancet Oncol (2012) 0.83

Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst (2014) 0.82

Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology (2012) 0.82

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death. Br J Cancer (2014) 0.82

Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study. Cancer Res (2014) 0.82

Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids (2014) 0.82

Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol. Br J Pharmacol (2014) 0.80

Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. Breast Cancer Res Treat (2014) 0.80

A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause (2014) 0.80

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol Cell Endocrinol (2015) 0.80

A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer (2014) 0.79

New antiresorptive therapies for postmenopausal osteoporosis. J Menopausal Med (2015) 0.79

Avoiding the bad and enhancing the good of soy supplements in breast cancer. J Natl Cancer Inst (2014) 0.78

Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev (2016) 0.78

Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev (2016) 0.78

The breast cancer epidemic: 10 facts. Linacre Q (2014) 0.76

Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. Eur J Cancer (2014) 0.76

A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. Obstet Gynecol Int (2015) 0.76

Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. Br J Clin Pharmacol (2015) 0.76

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget (2016) 0.76

Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells. Mol Cancer Res (2015) 0.76

Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. Breast Cancer Res Treat (2016) 0.75

Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. Menopause (2016) 0.75

The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk. Endocrinol Metab Clin North Am (2015) 0.75

Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf (2015) 0.75

Reproductive endocrinology: Estrogen use and breast cancer--an issue resolved? Nat Rev Endocrinol (2012) 0.75

Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast Cancer Res (2014) 0.75

Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget (2016) 0.75

Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo. PLoS One (2016) 0.75

Breast cancer: Risk and mortality after oestrogen-alone therapy--is it safe? Nat Rev Clin Oncol (2012) 0.75

Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene. Ther Clin Risk Manag (2016) 0.75

Articles cited by this

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39

Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet (1997) 10.28

Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19

Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics (2000) 6.19

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81

Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet (2005) 5.20

Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80

Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31

Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA (2009) 3.18

Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 3.04

Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol (2005) 3.01

Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79

Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst (2005) 2.10

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00

Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94

Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst (2003) 1.92

The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? J Clin Oncol (2008) 1.83

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res (2009) 1.75

Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res (2000) 1.73

Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control (1996) 1.58

Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.55

Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol (2003) 1.43

Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med (2006) 1.40

Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG (2002) 1.37

Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol (2009) 1.35

Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology (2001) 1.28

Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.25

Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol (2002) 1.20

Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res (2008) 1.16

The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev (2007) 1.15

Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst (1999) 1.08

Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med (2009) 1.07

The menopause: health implications and clinical management. J Am Geriatr Soc (1993) 1.03

Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol (2010) 1.03

Mammographic screening and risk factors for breast cancer. Am J Epidemiol (2009) 0.99

Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer (2005) 0.95

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat (2010) 0.95

The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer (2011) 0.91

Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf (2010) 0.91

Invited commentary: screening as a nuisance variable in cancer epidemiology: methodological considerations. Am J Epidemiol (2003) 0.91

New and translational perspectives of oestrogen deprivation in breast cancer. Mol Cell Endocrinol (2011) 0.87

Effects of estrogen-only treatment in postmenopausal women. JAMA (2004) 0.84

Menopause-related workload in general practice 1996-2005: a retrospective study in the UK. Fam Pract (2010) 0.79

Articles by these authors

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 11.39

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50

Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05

Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52

A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70

Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63

The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32

Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19

A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40

Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51

Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16

Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA (2008) 5.92

HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol (2008) 5.87

Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86

Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75

Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67

Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65

Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13

Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med (2010) 5.05

Physical activity, including walking, and cognitive function in older women. JAMA (2004) 4.90

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85

Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83

Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82

Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80